Optimizing Biospecimen Collection for CAR-T and Cell Therapy Research

Photo Credit: CDC/ Mildred Galton

Chimeric antigen receptor T cell (CAR-T) therapy has transformed oncology, turning previously fatal hematologic malignancies into manageable chronic conditions for many patients. But the clinical success of these living drugs depends fundamentally on the quality of the starting biospecimens used throughout development — from target validation through commercial manufacturing scale-up.

As the field expands beyond CD19-targeted blood cancers to solid tumors, autoimmune conditions, and infectious diseases, the biospecimen supply chain becomes a critical determinant of both research velocity and therapeutic product quality.

The path from patient-derived cells to therapeutic-grade CAR-T products spans multiple phases, each with distinct biospecimen requirements. Early discovery may use Human PBMCs from healthy donors to establish proof-of-concept for novel CAR constructs. Process development demands larger-scale Human Leukopak preparations to optimize manufacturing and establish critical quality attributes. Clinical translation requires GMP Leukopak starting material meeting pharmaceutical-grade specifications with full regulatory documentation.

At Sanguine, our portfolio spans this entire spectrum, enabling seamless progression from basic research through clinical manufacturing while maintaining consistent quality standards and donor population diversity across the United States.

Discovery Phase: Target Validation and CAR Construct Optimization

CAR-T development begins by identifying tumor-associated antigens suitable for targeting and engineering receptors that recognize these targets with appropriate specificity and affinity. This phase typically uses Human CD3+ T Cells isolated from healthy donor Human PBMCs to evaluate CAR function in vitro.[1] Cell numbers stay modest — 5–20 million T cells per construct tested — but viability and functional competence are critical as researchers screen dozens of CAR variants.

The diversity of T cell subsets in the starting population significantly influences CAR-T product characteristics. Naive T cells (CD45RA+CCR7+) show superior expansion and persistence in vivo compared with terminally differentiated effector cells, making their representation an important quality consideration.[2] Central memory T cells (CD45RO+CCR7+) balance proliferative capacity with immediate effector function. Researchers optimizing CAR designs benefit from biospecimens with documented subset composition, enabling correlation between starting phenotype and engineered product characteristics.

Functional validation of CAR constructs requires target-expressing cell lines, patient-derived Human Plasma containing relevant soluble antigens, and sometimes target-positive primary tumor cells for co-culture. Human CD56+ NK Cells serve as controls, helping distinguish CAR-mediated cytotoxicity from non-specific natural killer activity.[3] This multi-specimen approach ensures robust target validation before progressing to more expensive process development.

Process Development: Manufacturing Protocol Optimization

Moving from discovery to process development requires scaling cell numbers while maintaining product quality. Human Leukopak products collected by leukapheresis provide the yields needed — typically 1–5 × 10^10 total nucleated cells per collection, enabling dozens of manufacturing runs from single donors.[4] This scale supports systematic evaluation of media formulations, activation conditions, transduction parameters, and expansion protocols without confounding donor-to-donor variability.

Process robustness testing demands biospecimens representing the diversity of the patient population. Healthy young donors with optimal T cell fitness may manufacture successfully using suboptimal protocols that fail with heavily pre-treated cancer patients with compromised immune systems.[5] Including Human Leukopak from older donors, patients with relevant comorbidities, and individuals on immunosuppressive medications identifies protocol weaknesses before clinical manufacturing. Sanguine’s access to over 70,000 donors with diverse profiles enables fit-for-purpose development cohorts.

Comparability studies between fresh and cryopreserved starting material are another key milestone. Fresh Human Whole Blood collections offer logistical simplicity for local manufacturing, while cryopreserved GMP Leukopak products enable centralized manufacturing with batch-production economies.[6] Demonstrating that cryopreserved starting material yields products meeting predefined specifications requires systematic comparability assessment across multiple donors and runs. Our standardized cryopreservation protocols minimize variability, supporting robust comparability data.

GMP Manufacturing: Clinical-Grade Starting Material Requirements

The transition to clinical manufacturing introduces regulatory requirements that transform biospecimen procurement from research supply into pharmaceutical component supply chain management. GMP Leukopak starting material must be collected under FDA-compliant protocols with comprehensive documentation — donor screening, infectious disease testing, collection procedures, and complete chain of custody.[7] Every batch requires certificates of analysis documenting sterility, mycoplasma status, endotoxin levels, viability, and cell composition.

Donor screening for clinical manufacturing extends beyond research-grade requirements. Serological testing for HIV-1/2, hepatitis B and C, HTLV-I/II, West Nile virus, Chagas disease, and syphilis must be completed within specified windows before collection using FDA-licensed or approved assays.[8] Nucleic acid testing (NAT) further reduces window-period risks for viral pathogens. Some protocols require CMV status screening, particularly for immunocompromised recipient populations where CMV reactivation presents significant risks.

Master cell bank strategies are an emerging approach, using healthy donor cells as universal starting material rather than patient-specific autologous manufacturing. This allogeneic approach demands even more rigorous qualification — HLA typing, T cell receptor editing to prevent graft-versus-host disease, and comprehensive genomic characterization.[9] Sanguine’s GMP Leukopak products can be collected with extended phenotypic characterization and genomic annotation supporting master cell bank qualification.

Biospecimen Requirements Across CAR-T Development Phases

Discovery and Target Validation Phase

The initial phase focuses on identifying suitable tumor antigens and engineering receptors with optimal binding. It uses relatively small cell numbers but requires diverse specimen types to comprehensively evaluate CAR function.

Essential Biospecimens for Discovery:

• Human CD3+ T Cells (5–20M cells per experiment) for CAR expression and basic function
• Human PBMCs (20–50M cells) for mixed lymphocyte reactions and specificity testing
• Target-positive tumor cell lines or patient-derived cells for cytotoxicity assays
• Human Plasma containing soluble target antigens for specificity validation
• Human CD56+ NK Cells as negative controls for antigen-specific killing
• Control Human Serum for complement-dependent cytotoxicity assessment
• Human Whole Blood for initial safety screening (cytokine release)

Key Quality Parameters:

• T cell viability ≥90% for consistent transduction efficiency
• Activation state documentation (CD25, CD69 expression)
• T cell receptor (TCR) diversity assessment via TRBV repertoire analysis
• Memory subset composition (naive, central memory, effector memory percentages)
• Donor serostatus for relevant pathogens
• Genomic annotation including age, sex, medication history
• Processing time from collection to cryopreservation <24 hours

Preclinical Development and Manufacturing Process Optimization

Moving from target validation to manufacturing protocol development requires larger cell numbers and more extensive characterization. Teams must de-risk protocols across diverse patient scenarios.

Essential Biospecimens for Process Development:

• Human Leukopak (10–20 leukopaks) from healthy donors for baseline process establishment
• Human Leukopak (5–10 leukopaks) from disease-relevant populations (cancer patients, elderly, immunosuppressed)
• GMP Leukopak (3–5 units) for GMP process transfer validation
• Matched Human Plasma from same donors for lot-matched plasma supplementation
• Human PBMCs from target patient population for potency assay development
• Human CD3+ T Cells for analytical method development and validation

Key Quality Parameters:

• TNC count consistency across leukopak lots (CV <30%)
• Mononuclear cell enrichment ≥90% post-density gradient separation
• CD4:CD8 ratio documentation for each lot
• Functional validation (proliferation, cytokine production) from each donor
• Complete genomic annotation enabling stratified analysis
• Full donor medical history including prior treatments
• Sterility and mycoplasma testing on all GMP units
• Documented processing conditions and storage history

Clinical Manufacturing and Commercial Scale-Up

Clinical-stage manufacturing demands the highest specifications with full regulatory traceability. Every biospecimen component must meet pharmaceutical-grade standards with comprehensive testing supporting BLA submissions.

Essential Biospecimens for Clinical Manufacturing:

• GMP Leukopak collected under FDA-compliant protocols
• Donor qualification per 21 CFR Part 1271 requirements
• Full infectious disease testing panel with documented results
• Certificates of analysis for all critical quality attributes
• Chain of custody documentation from collection through delivery
• Backup Human PBMCs for potency assay execution
• Reference Human CD3+ T Cells for assay qualification
• Human Plasma from matched donors for autologous culture supplementation

Key Quality Parameters:

• All FDA donor screening requirements met and documented
• GMP collection facility qualifications current
• Sterility assurance level appropriate for pharmaceutical manufacturing
• Endotoxin levels ≤0.5 EU/mL tested by LAL assay
• Complete batch records with traceability to donor
• Temperature monitoring throughout collection and transit
• Validated cryopreservation protocols with stability data
• Real-time release testing capabilities

Critical Success Factors in CAR-T Biospecimen Supply

Vendor qualification is perhaps the most important strategic decision in CAR-T biospecimen sourcing. The provider must demonstrate current GMP compliance and the operational maturity to support long-term supply through clinical development and potential commercialization.[10] Regulatory inspections during BLA review scrutinize starting material supplier qualifications, making vendor robustness critical.

Supply chain redundancy protects against disruptions that could delay trials or interrupt patient treatment. Qualifying multiple collection sites across the United States provides geographic redundancy while maintaining consistent quality. Sanguine’s network spans major metropolitan areas and enables rapid mobilization of backup collection capacity.[11] This distributed approach also supports patient convenience in autologous collection scenarios.

Long-term supply agreements with flexible capacity support programs through uncertain growth. Early-phase trials may need 5–10 GMP leukopaks monthly, while Phase III can demand hundreds of collections. Commercial launch can require thousands annually.[12] Providers who scale operations while maintaining quality are essential for programs targeting commercial success. Our experience supporting programs from Phase I through commercial launch reflects this capability.

Autologous vs. Allogeneic Manufacturing: Biospecimen Implications

The autologous paradigm — each patient serves as donor and recipient — presents unique challenges versus allogeneic off-the-shelf approaches. Patients requiring CAR-T often have undergone extensive prior treatment including cytotoxic chemotherapy, radiation, and immunosuppression that compromises T cell fitness.[13] Lymphopenia, T cell exhaustion, and altered immune constitution affect manufacturing success rates and final product characteristics.

Starting material assessment is critical in autologous collection to identify patients whose T cells may fail to manufacture. Flow cytometric analysis of Human Whole Blood before apheresis can predict outcomes, with absolute lymphocyte counts, CD4:CD8 ratios, and activation markers serving as informative biomarkers.[14] Pre-screening enables patient selection or lymphodepleting conditioning to improve collection yields.

Allogeneic approaches using healthy donor cells as universal starting material transform requirements. Master cell bank establishment from carefully selected donors with optimal T cell phenotypes enables consistent manufacturing.[15] Donor screening expands to include HLA typing, TCR diversity assessment, and comprehensive genomic characterization. GMP Leukopak collections from these qualified donors undergo extensive sterility, endotoxin, mycoplasma, and adventitious agent screening before lot release.

Genomic Annotation: Predicting Manufacturing Success

The depth of clinical and phenotypic information accompanying biospecimens directly affects researchers’ ability to optimize protocols and predict product quality. Complete medication histories reveal immunosuppressants, corticosteroids, or chemotherapy exposures that may affect T cell function and expansion.[16] Recent infection history identifies donors whose immune systems may be activated or exhausted.

Laboratory values — complete blood counts, metabolic panels, immune subset quantification — provide quantitative context for interpreting outcomes. A patient with lymphopenia (absolute lymphocyte count <1000/μL) may need larger apheresis volumes.[17] Elevated inflammatory markers (CRP, ESR) suggest immune activation that could affect transduction efficiency or expansion. Sanguine’s comprehensive genomic annotation captures these parameters, enabling stratification of manufacturing outcomes by patient characteristics.

Longitudinal data collection throughout CAR-T trials reveals relationships between pre-manufacturing patient characteristics and clinical responses. Patients who successfully manufacture high-quality products may differ systematically from failures in prior treatment exposure, comorbidity burden, or baseline immune profile.[18] Providers who support longitudinal collection — from pre-apheresis baseline through post-infusion follow-up — enable these analyses.

Laboratory Processing: From Apheresis to Cryopreserved Product

The processing cascade from apheresis to cryopreserved starting material introduces multiple variables affecting final quality. Anticoagulant choice during apheresis — typically ACD-A or sodium citrate — impacts subsequent processing and functional assays.[19] Processing delays between collection and cryopreservation must be minimized (ideally <24 hours) to prevent activation, exhaustion, or apoptosis that compromise yield.

Density gradient centrifugation remains the gold standard for mononuclear cell enrichment from leukapheresis products, separating lymphocytes and monocytes from granulocytes and erythrocytes by buoyant density. Ficoll-Paque or equivalent media enable >90% mononuclear cell recovery with minimal granulocyte contamination.[20] But gradient centrifugation applies mechanical stress and osmotic shock that can activate cells if not carefully controlled. Standardized protocols — specified g-forces, acceleration/deceleration profiles, and temperature control — ensure lot-to-lot consistency.

Cryopreservation protocols strongly influence post-thaw recovery and function. Controlled-rate freezing at about 1°C per minute minimizes ice crystal formation, while cryoprotectant media (typically 10% DMSO with human serum albumin) protects against osmotic injury.[21] Storage in vapor-phase liquid nitrogen maintains integrity during long-term banking. Sanguine’s validated protocols ensure >85% post-thaw viability with maintained functional competence across extended storage.

Donor Selection Strategies for CAR-T Development Programs

Strategic donor selection significantly impacts research efficiency and manufacturing success. Healthy donor selections for process development should mirror the intended patient population in age distribution, comorbidity prevalence, and prior treatment exposure.[22] A therapy targeting elderly patients with multiply-relapsed lymphoma benefits from process development using age-matched, treatment-experienced donors rather than only young healthy individuals.

HLA typing matters in both autologous and allogeneic contexts. Autologous CAR-T obviates HLA matching (donor and recipient are the same), while allogeneic approaches require careful consideration of HLA-mediated rejection.[23] Off-the-shelf products incorporating HLA deletion or modification require starting material from HLA-typed donors. Sanguine’s donor characterization includes HLA typing supporting these requirements.

CMV serostatus is another often-overlooked donor characteristic. CMV-seropositive individuals harbor large populations of CMV-specific memory T cells that may constitute 10–20% of the total CD8+ compartment in some donors.[24] These antigen-experienced cells have distinct phenotypic and functional properties, potentially affecting CAR-T expansion and persistence. Controlling for CMV serostatus during process development isolates this variable’s contribution to manufacturing variability.

Quality Control Testing Throughout Development Pipeline

Comprehensive QC at every phase protects research investments and accelerates timelines by catching issues early. Starting material characterization should extend well beyond viability to include functional validation, phenotypic profiling, and sterility assurance.

Pre-Manufacturing Quality Assessment:

• Total and viable cell counts by automated cell counter
• Cell viability by flow cytometry (7-AAD or PI exclusion)
• Immunophenotyping: CD3, CD4, CD8, CD45RA, CCR7, PD-1, TIM-3
• T cell activation markers: CD25, CD69, HLA-DR
• Functional validation: anti-CD3/CD28 stimulation with proliferation assessment
• Cytokine production capacity: IFN-γ, TNF-α, IL-2 by ELISA or multiplex
• Sterility testing: 14-day bacterial and fungal cultures
• Mycoplasma testing by PCR
• Endotoxin quantification by LAL assay
• Transduction efficiency pilot with control vector

Post-Manufacturing Product Testing:

• CAR expression by flow cytometry (target ≥30% CAR+ cells)
• T cell subset composition in final product
• Residual vector analysis
• Expansion fold-change from starting material
• Viability and cell count for dose calculation
• Sterility and mycoplasma reconfirmation
• Endotoxin final product testing
• Identity testing confirming autologous source
• Potency assays: target-specific cytotoxicity, cytokine release
• Replication-competent lentivirus testing (if applicable)

Sanguine’s Integrated CAR-T Biospecimen Solutions

Our approach addresses every phase from discovery through commercial manufacturing. Research-grade Human PBMCs and Human CD3+ T Cells support early target validation with consistent quality and rapid turnaround. Process development teams access diverse Human Leukopak cohorts representing intended patient populations.

Clinical-stage programs transition to GMP Leukopak products collected under full FDA compliance with comprehensive regulatory documentation. Our Quality Management System maintains ISO 13485:2016 certification. From study design to receipt of samples, our scientific support team collaborates with developers to specify collection protocols, QC parameters, and documentation supporting regulatory submissions.[25]

Custom collection services accommodate study-specific requirements including specialized apheresis protocols, extended phenotypic characterization, or coordinated collection of matched plasma and cellular products. Geographic reach across the United States enables access to diverse donor populations and supports multi-site trials. Real-time inventory visibility and rapid fulfillment (often same-day for fresh collections) support the dynamic timelines of clinical cell therapy programs.

Emerging Trends in Cell Therapy Biospecimen Requirements

The field continues evolving beyond classical CD19-targeted CAR-T, introducing new requirements. CAR-NK cells derived from Human CD56+ NK Cells offer potential advantages including reduced cytokine release syndrome risk and HLA-independent tumor recognition.[26] These modalities require distinct manufacturing protocols and specifications.

Tumor-infiltrating lymphocyte (TIL) therapy is another expanding modality requiring specialized tissue biospecimens. While CAR-T sources cells from peripheral blood, TIL therapy begins with tumor resection specimens providing tumor-reactive T cells.[27] Coordinating blood-derived collection (Human PBMCs, Human Plasma) with tissue procurement supports immune profiling comparing tumor-infiltrating and peripheral populations.

Regulatory evolution continues shaping requirements. Recent FDA guidance emphasizes manufacturing process validation, starting material specifications, and demonstration of product consistency across runs.[28] Providers who proactively adopt evolving expectations position customers for success. Sanguine’s commitment to quality and regulatory foresight keeps our solutions compliant with current and anticipated requirements.

Geographic and Demographic Diversity in Cell Therapy Development

Population diversity in biospecimen sourcing directly impacts the generalizability of CAR-T effectiveness across diverse patients. Immune cell characteristics — subset frequencies, activation thresholds, cytokine production, exhaustion susceptibility — vary across demographic groups due to genetic background and environment.[29] Therapies optimized only on cells from limited demographics may show reduced efficacy in underrepresented populations.

Access to oncology biospecimens from demographically diverse cancer patients enables investigation of ethnic disparities in manufacturing success and clinical response. African American patients with multiple myeloma, for example, show distinct disease biology and treatment response patterns compared with European ancestry populations.[30] Process development incorporating diverse biospecimens improves the likelihood that optimized protocols succeed across broad populations.

Sanguine’s direct-to-donor model across the United States enables access to underrepresented populations often excluded from research — rural communities, non-English speaking populations, and patients with complex comorbidities. This breadth supports health equity while pragmatically improving the likelihood of broad commercial success.

---

Check Our Inventory

Accelerate your CAR-T and cell therapy development with premium-quality biospecimens at every research phase.

Explore our comprehensive oncology biospecimens inventory or contact our scientific team to discuss custom collection protocols tailored to your development needs.

Request a Custom Quote →

---

Ethical Sourcing and Regulatory Compliance

All Sanguine biospecimens are collected under IRB-approved protocols ensuring ethical treatment of donors and rigorous informed consent. Our HIPAA-compliant data management protects donor privacy while enabling researchers to access comprehensive genomic annotation. GMP Leukopak products meet 21 CFR Part 1271 requirements for human cells and tissues, with full donor qualification documentation and infectious disease testing using FDA-licensed assays.

Quality certifications including ISO 9001:2015 and ISO 13485:2016 demonstrate our commitment to pharmaceutical-grade quality management. Every specimen is designated Research Use Only (RUO) unless specifically manufactured under clinical protocols, with clear documentation of intended application scope and regulatory status.

---

References

1. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-1365. doi:10.1126/science.aar6711
2. Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492-500. doi:10.1038/leu.2015.247
3. Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545-553. doi:10.1056/NEJMoa1910607
4. Stroncek DF, Fellowes V, Pham C, et al. Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies. J Transl Med. 2004;2:23. doi:10.1186/1479-5876-2-23
5. Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563-571. doi:10.1038/s41591-018-0010-1
6. Tyagarajan S, Spencer T, Smith J. Optimizing CAR-T cell manufacturing processes during pivotal clinical trials. Mol Ther Methods Clin Dev. 2020;16:136-144. doi:10.1016/j.omtm.2019.11.018
7. Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92-101. doi:10.1016/j.omtm.2016.12.006
8. Food and Drug Administration. Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). August 2007.
9. Benjamin R, Graham C, Yallop D, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020;396(10266):1885-1894. doi:10.1016/S0140-6736(20)32334-5
10. Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018;53:164-181. doi:10.1016/j.copbio.2018.01.025
11. Lopes AG, Ip BC, Pritchett C, et al. Regional considerations for CAR-T therapy in lymphoma patients. Curr Hematol Malig Rep. 2021;16(2):161-169. doi:10.1007/s11899-021-00615-5
12. Abou-El-Enein M, Elsallab M, Feldman SA, et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2021;2(5):408-422. doi:10.1158/2643-3230.BCD-21-0084
13. Stein AM, Grupp SA, Levine JE, et al. Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor-T cells. CPT Pharmacometrics Syst Pharmacol. 2019;8(5):285-295. doi:10.1002/psp4.12388
14. Ghassemi S, Nunez-Cruz S, O’Connor RS, et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol Res. 2018;6(9):1100-1109. doi:10.1158/2326-6066.CIR-17-0405
15. Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113-117. doi:10.1038/nature21405
16. Garfall AL, Maus MV, Hwang WT, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373(11):1040-1047. doi:10.1056/NEJMoa1504542
17. Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116. doi:10.1126/scitranslmed.aaf8621
18. Deng Q, Han G, Puebla-Osorio N, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020;26(12):1878-1887. doi:10.1038/s41591-020-1061-7
19. Stroncek DF, Lee DW, Ren J, et al. Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells. J Transl Med. 2017;15(1):59. doi:10.1186/s12967-017-1160-5
20. Kotlan B, Simsa P, Teillaud JL, et al. Novel methods for the analysis of antigen-specific T-cell immune responses in cancer patients. Cancer Immunol Immunother. 2004;53(8):707-718. doi:10.1007/s00262-003-0493-3
21. Perica K, Curran KJ, Brentjens RJ, Giralt SA. Building a CAR garage: preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center. Biol Blood Marrow Transplant. 2018;24(6):1135-1141. doi:10.1016/j.bbmt.2018.02.018
22. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372-385. doi:10.1038/s41571-019-0184-6
23. Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374):eaaj2013. doi:10.1126/scitranslmed.aaj2013
24. Pera A, Campos C, López N, et al. Immunosenescence: Implications for response to infection and vaccination in older people. Maturitas. 2015;82(1):50-55. doi:10.1016/j.maturitas.2015.05.004
25. Roddie C, O’Reilly M, Dias Alves Pinto J, Vispute K, Lowdell M. Manufacturing chimeric antigen receptor T cells: issues and challenges. Cytotherapy. 2019;21(3):327-340. doi:10.1016/j.jcyt.2018.11.009
26. Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for cancer immunotherapy. Mol Ther. 2017;25(8):1769-1781. doi:10.1016/j.ymthe.2017.06.012
27. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62-68. doi:10.1126/science.aaa4967
28. Food and Drug Administration. Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). Guidance for Industry. January 2020.
29. Nédélec Y, Sanz J, Baharian G, et al. Genetic ancestry and natural selection drive population differences in immune responses to pathogens. Cell. 2016;167(3):657-669.e21. doi:10.1016/j.cell.2016.09.025
30. Costa LJ, Gonsalves WI, Kumar SK. Early mortality in multiple myeloma. Leukemia. 2015;29(9):1616-1618. doi:10.1038/leu.2015.122

Sanguine supplies research-grade human CD4+ T cells for studies like this.